These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 20973483)
1. In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease. Shook BC; Rassnick S; Osborne MC; Davis S; Westover L; Boulet J; Hall D; Rupert KC; Heintzelman GR; Hansen K; Chakravarty D; Bullington JL; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Palmer D; Reyes M; Demarest K; Tang Y; Rhodes K; Jackson PF J Med Chem; 2010 Nov; 53(22):8104-15. PubMed ID: 20973483 [TBL] [Abstract][Full Text] [Related]
2. Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease. Shook BC; Rassnick S; Wallace N; Crooke J; Ault M; Chakravarty D; Barbay JK; Wang A; Powell MT; Leonard K; Alford V; Scannevin RH; Carroll K; Lampron L; Westover L; Lim HK; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Rhodes K; Jackson PF J Med Chem; 2012 Feb; 55(3):1402-17. PubMed ID: 22239465 [TBL] [Abstract][Full Text] [Related]
3. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease. Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719 [TBL] [Abstract][Full Text] [Related]
4. 2-Aminopyrimidines as dual adenosine A1/A2A antagonists. Robinson SJ; Petzer JP; Terre'Blanche G; Petzer A; van der Walt MM; Bergh JJ; Lourens AC Eur J Med Chem; 2015 Nov; 104():177-88. PubMed ID: 26462195 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118 [TBL] [Abstract][Full Text] [Related]
6. Antiparkinsonian effects of novel adenosine A(2A) receptor antagonists. Drabczyńska A; Zygmunt M; Sapa J; Filipek B; Müller CE; Kieć-Kononowicz K Arch Pharm (Weinheim); 2011 Jan; 344(1):20-7. PubMed ID: 21213348 [TBL] [Abstract][Full Text] [Related]
7. Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Neustadt BR; Hao J; Lindo N; Greenlee WJ; Stamford AW; Tulshian D; Ongini E; Hunter J; Monopoli A; Bertorelli R; Foster C; Arik L; Lachowicz J; Ng K; Feng KI Bioorg Med Chem Lett; 2007 Mar; 17(5):1376-80. PubMed ID: 17236762 [TBL] [Abstract][Full Text] [Related]
8. Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists. Zhang X; Rueter JK; Chen Y; Moorjani M; Lanier MC; Lin E; Gross RS; Tellew JE; Williams JP; Lechner SM; Markison S; Joswig T; Malany S; Santos M; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Saunders J; Slee DH Bioorg Med Chem Lett; 2008 Mar; 18(6):1778-83. PubMed ID: 18329269 [TBL] [Abstract][Full Text] [Related]
9. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715 [TBL] [Abstract][Full Text] [Related]
10. Identification of a New Series of Potent Adenosine A Yang Z; Li L; Zheng J; Ma H; Tian S; Li J; Zhang H; Zhen X; Zhang X ACS Chem Neurosci; 2016 Nov; 7(11):1575-1584. PubMed ID: 27569066 [TBL] [Abstract][Full Text] [Related]